Advertisement
News
Advertisement

Boston Scientific hits 4-year high following asthma treatment trial results

Fri, 09/06/2013 - 2:07pm
Mass Device

Boston Scientific hits new Wall Street highs after the Journal of Allergy & Clinical Immunology publishes a study touting the safety and efficacy of the Alair bronchial thermoplasty system.

Boston Scientific hits 4-year high following asthma treatment trial results

Boston Scientific (NYSE:BSX) keeps hitting high notes on Wall Street, most recently setting a new 4-year record in the days following the publication of a new study touting the company's Alair bronchial thermoplasty system.

The medical device giant announced this week that the Alair system proved safe and effective in reducing severe asthma attacks over at least 5 years, and BSX shares jumped to $11.67 apiece on September 5, 2013, a high not seen since September 2009.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading